383 related articles for article (PubMed ID: 28723515)
1. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
2. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
4. [Castration resistance mechanisms in prostate cancer.].
Martínez-Breijo S; Chantada-Abal V; Aller-Rodríguez M; Bohórquez-Cruz M; Sacristán-Lista F; Ponce-Díaz J; Vázquez-Martul D; Lamas-Díaz L
Arch Esp Urol; 2018 Sep; 71(8):628-638. PubMed ID: 30319123
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
6. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
Tilki D; Evans CP
Can J Urol; 2014 Apr; 21(2 Supp 1):7-13. PubMed ID: 24775718
[TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
8. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
9. The Molecular Evolution of Castration-resistant Prostate Cancer.
Ceder Y; Bjartell A; Culig Z; Rubin MA; Tomlins S; Visakorpi T
Eur Urol Focus; 2016 Dec; 2(5):506-513. PubMed ID: 28723516
[TBL] [Abstract][Full Text] [Related]
10. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
11. Role of Androgen Receptor in Prostate Cancer: A Review.
Fujita K; Nonomura N
World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of androgen receptor alterations in prostate cancer.
Jernberg E; Bergh A; Wikström P
Endocr Connect; 2017 Nov; 6(8):R146-R161. PubMed ID: 29030409
[TBL] [Abstract][Full Text] [Related]
15. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer.
Crowley F; Sterpi M; Buckley C; Margetich L; Handa S; Dovey Z
Res Rep Urol; 2021; 13():457-472. PubMed ID: 34235102
[TBL] [Abstract][Full Text] [Related]
17. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
[TBL] [Abstract][Full Text] [Related]
18. New insights for drug resistance in metastatic castration-resistant prostate cancer.
Kushwaha PP; Gupta S
Cancer Drug Resist; 2022; 5(3):846-849. PubMed ID: 36176749
[TBL] [Abstract][Full Text] [Related]
19. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
20. PROTACs targeting androgen receptor signaling: potential therapeutic agents for castration-resistant prostate cancer.
Zhang Y; Ming A; Wang J; Chen W; Fang Z
Pharmacol Res; 2024 May; ():107234. PubMed ID: 38815882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]